Medication Adherence in a Transdiagnostic First-Episode Psychosis Sample

References (55)

1. Perälä J, Suvisaari J, Saarni SI, et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry. 2007;64(1):19–28. PubMed CrossRef
2. Awad AG, Voruganti LN. The burden of schizophrenia on caregivers: a review. Pharmacoeconomics. 2008;26(2):149–162. PubMed CrossRef
3. Fekadu W, Mihiretu A, Craig TKJ, et al. Multidimensional impact of severe mental illness on family members: systematic review. BMJ Open. 2019;9(12):e032391. PubMed CrossRef
4. Cloutier M, Aigbogun MS, Guerin A, et al. The economic burden of schizophrenia in the United States in 2013. J Clin Psychiatry. 2016;77(6):764–771. PubMed CrossRef
5. Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56(3):241–247. PubMed CrossRef
6. Gitlin M, Nuechterlein K, Subotnik KL, et al. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am J Psychiatry. 2001;158(11):1835–1842. PubMed CrossRef
7. Subotnik KL, Nuechterlein KH, Ventura J, et al. Risperidone nonadherence and return of positive symptoms in the early course of schizophrenia. Am J Psychiatry. 2011;168(3):286–292. PubMed CrossRef
8. Morken G, Widen JH, Grawe RW. Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia. BMC Psychiatry. 2008;8(1):32. PubMed CrossRef
9. Hill M, Crumlish N, Whitty P, et al. Nonadherence to medication four years after a first episode of psychosis and associated risk factors. Psychiatr Serv. 2010;61(2):189–192. PubMed CrossRef
10. Novick D, Haro JM, Suarez D, et al. Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Res. 2010;176(2-3):109–113. PubMed CrossRef
11. Lindenmayer JP, Liu-Seifert H, Kulkarni PM, et al. Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response. J Clin Psychiatry. 2009;70(7):990–996. PubMed CrossRef
12. Takeuchi H, Siu C, Remington G, et al. Does relapse contribute to treatment resistance? antipsychotic response in first- vs second-episode schizophrenia. Neuropsychopharmacology. 2019;44(6):1036–1042. PubMed CrossRef
13. Breitborde NJ, Srihari VH, Woods SW. Review of the operational definition for first-episode psychosis. Early Interv Psychiatry. 2009;3(4):259–265. PubMed CrossRef
14. Marshall M, Lewis S, Lockwood A, et al. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry. 2005;62(9):975–983. PubMed CrossRef
15. Harrigan SM, McGorry PD, Krstev H. Does treatment delay in first-episode psychosis really matter? Psychol Med. 2003;33(1):97–110. PubMed CrossRef
16. Penttilä M, Jääskeläinen E, Hirvonen N, et al. Duration of untreated psychosis as predictor of long-term outcome in schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2014;205(2):88–94. PubMed CrossRef
17. Coldham EL, Addington J, Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand. 2002;106(4):286–290. PubMed CrossRef
18. Tan C, Abdin E, Liang W, et al. Medication adherence in first-episode psychosis patients in Singapore. Early Interv Psychiatry. 2019;13(4):780–788. PubMed CrossRef
19. Raghavan V, Mohan G, Gopal S, et al. Medication adherence in first-episode psychosis and its association with psychopathology. Indian J Psychiatry. 2019;61(4):342–346. PubMed CrossRef
20. Kampman O, Laippala P, Väänänen J, et al. Indicators of medication compliance in first-episode psychosis. Psychiatry Res. 2002;110(1):39–48. PubMed CrossRef
21. Quach PL, Mors O, Christensen TO, et al. Predictors of poor adherence to medication among patients with first-episode schizophrenia-spectrum disorder. Early Interv Psychiatry. 2009;3(1):66–74. PubMed CrossRef
22. Steger KA, Cassidy C, Rabinovitch M, et al. Impact of symptom resolution on medication adherence in first episode psychosis. Psychiatry Res. 2012;196(1):45–51. PubMed CrossRef
23. Perkins DO, Johnson JL, Hamer RM, et al; HGDH Research Group. Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophr Res. 2006;83(1):53–63. PubMed CrossRef
24. Lambert M, Conus P, Cotton S, et al. Prevalence, predictors, and consequences of long-term refusal of antipsychotic treatment in first-episode psychosis. J Clin Psychopharmacol. 2010;30(5):565–572. PubMed CrossRef
25. Kovasznay B, Fleischer J, Tanenberg-Karant M, et al. Substance use disorder and the early course of illness in schizophrenia and affective psychosis. Schizophr Bull. 1997;23(2):195–201. PubMed CrossRef
26. Mutsatsa SH, Joyce EM, Hutton SB, et al. Clinical correlates of early medication adherence: West London first episode schizophrenia study. Acta Psychiatr Scand. 2003;108(6):439–446. PubMed CrossRef
27. Leclerc E, Noto C, Bressan RA, et al. Determinants of adherence to treatment in first-episode psychosis: a comprehensive review. Br J Psychiatry. 2015;37(2):168–176. PubMed CrossRef
28. Shinn AK, Bolton KW, Karmacharya R, et al. McLean OnTrack: a transdiagnostic program for early intervention in first-episode psychosis. Early Interv Psychiatry. 2017;11(1):83–90. PubMed CrossRef
29. Shinn AK, Cawkwell PB, Bolton K, et al. Return to college after a first episode of psychosis. Schizophr Bull Open. 2020;1(1):a041. PubMed CrossRef
30. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)––a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–381. PubMed CrossRef
31. Valenstein M, Kavanagh J, Lee T, et al. Using a pharmacy-based intervention to improve antipsychotic adherence among patients with serious mental illness. Schizophr Bull. 2011;37(4):727–736. PubMed CrossRef
32. Karve S, Cleves MA, Helm M, et al. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin. 2009;25(9):2303–2310. PubMed CrossRef
33. Caseiro O, Pérez-Iglesias R, Mata I, et al. Predicting relapse after a first episode of non-affective psychosis: a three-year follow-up study. J Psychiatr Res. 2012;46(8):1099–1105. PubMed CrossRef
34. Cassidy CM, Rabinovitch M, Schmitz N, et al. A comparison study of multiple measures of adherence to antipsychotic medication in first-episode psychosis. J Clin Psychopharmacol. 2010;30(1):64–67. PubMed CrossRef
35. Jónsdóttir H, Opjordsmoen S, Birkenaes AB, et al. Medication adherence in outpatients with severe mental disorders: relation between self-reports and serum level. J Clin Psychopharmacol. 2010;30(2):169–175. PubMed CrossRef
36. Cawkwell PB, Bolton KW, Karmacharya R, et al. Two-year diagnostic stability in a real-world sample of individuals with early psychosis. Early Interv Psychiatry. 2020;14(6):751–754. PubMed CrossRef
37. Essentials PP. Antipsychotic Dose Equivalents. American Association of Psychiatric Pharmacists (AAPP) website. https://aapp.org/guideline/essentials/antipsychotic-dose-equivalents. Accessed April 1, 2023.
38. Perkins DO, Gu H, Weiden PJ, et al; Comparison of Atypicals in First Episode study group. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. J Clin Psychiatry. 2008;69(1):106–113. PubMed CrossRef
39. Opolka JL, Rascati KL, Brown CM, et al. Role of ethnicity in predicting antipsychotic medication adherence. Ann Pharmacother. 2003;37(5):625–630. PubMed CrossRef
40. Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63(10):892–909. PubMed CrossRef
41. McQuaid EL, Landier W. Cultural issues in medication adherence: disparities and directions. J Gen Intern Med. 2018;33(2):200–206. PubMed CrossRef
42. Haskard Zolnierek KB, Dimatteo MR. Physician communication and patient adherence to treatment: a meta-analysis. Med Care. 2009;47(8):826–834. PubMed CrossRef
43. Freudenreich O. Psychotic Disorders: A Practical Guide. 2nd ed. Springer International Publishing; 2020.
44. Høyer G. On the justification for civil commitment. Acta Psychiatr Scand suppl. 2000;101(399):65–71. PubMed CrossRef
45. David AS. Insight and psychosis. Br J Psychiatry. 1990;156(6):798–808. PubMed CrossRef
46. Amador XF, Strauss DH, Yale SA, et al. Assessment of insight in psychosis. (see comments) Am J Psychiatry. 1993;150(6):873–879. PubMed CrossRef
47. Beck AT, Baruch E, Balter JM, et al. A new instrument for measuring insight: the Beck Cognitive Insight Scale. Schizophr Res. 2004;68(2–3):319–329. PubMed CrossRef
48. Capdevielle D, Norton J, Aouizerate B, et al; FACE-SCZ Group. Comparison of three scales (BIS, SUMD and BCIS) for measuring insight dimensions and their evolution after one-year of follow-up: findings from the FACE-SZ Cohort. Psychiatry Res. 2021;303:114044. PubMed CrossRef
49. Droulout T, Liraud F, Verdoux H. Relationships between insight and medication adherence in subjects with psychosis [Influence de la conscience du trouble et de la perception subjective du traitement sur l’observance medicamenteuse dans les troubles psychotiques]. Encephale. 2003;29(5):430–437. PubMed
50. Novick D, Montgomery W, Treuer T, et al. Relationship of insight with medication adherence and the impact on outcomes in patients with schizophrenia and bipolar disorder: results from a 1-year European outpatient observational study. BMC Psychiatry. 2015;15(1):189. PubMed CrossRef
51. Lui SSY, Lam JPY, Lam JWS, et al. Cognitive insight is correlated with cognitive impairments and contributes to medication adherence in schizophrenia patients. Asian J Psychiatr. 2021;60:102644. PubMed CrossRef
52. David AS. Insight and psychosis: the next 30 years. Br J Psychiatry. 2020;217(3):521–523. PubMed CrossRef
53. Pijnenborg GH, van Donkersgoed RJ, David AS, et al. Changes in insight during treatment for psychotic disorders: a meta-analysis. Schizophr Res. 2013;144(1-3):109–117. PubMed CrossRef
54. Swofford CD, Kasckow JW, Scheller-Gilkey G, et al. Substance use: a powerful predictor of relapse in schizophrenia. Schizophr Res. 1996;20(1-2):145–151. PubMed CrossRef
55. Hides L, Dawe S, Kavanagh DJ, et al. Psychotic symptom and cannabis relapse in recent-onset psychosis. prospective study. Br J Psychiatry. 2006;189(2):137–143. PubMed CrossRef